Cargando…
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Heritable changes in gene expression that are not based upon alterations in the DNA sequence are defined as epigenetics. The most common mechanisms of epigenetic regulation are the methylation of CpG islands within the DNA and the modification of amino acids in the N-terminal histone tails. In the l...
Autores principales: | Wagner, Julia M., Hackanson, Björn, Lübbert, Michael, Jung, Manfred |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020651/ https://www.ncbi.nlm.nih.gov/pubmed/21258646 http://dx.doi.org/10.1007/s13148-010-0012-4 |
Ejemplares similares
-
The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021) -
Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022) -
The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014) -
Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021) -
Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)